MedTrace Logo

Evaluation of the Effect of Kefir Consumption

NCT07522372 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2026-04-13

No results posted yet for this study

Summary

Many societies traditionally use fermentation as a means of producing beverages, whose microbial transformation is spontaneously triggered or facilitated by the addition of a catalyst (yeasts, bacteria). Kefir is a traditional beverage belonging to the latter category.

It is a probiotic that is supposed to modify the intestinal microbiota and the metabolites produced.

Links between kefir and metabolic syndromes (insulin resistance, etc.) have also been described in animal models. Very few clinical studies have evaluated the effects of kefir in humans.

A 'positive feeling' has also been described by people who consume kefir. Kefir could therefore have an effect on people's well-being.

Conditions

  • Emotion
  • Well-being

Interventions

OTHER

Consumption of a control beverage, non-fermented carbonated drink

Consumption of a control beverage, non-fermented carbonated drink and measurement of the concentrations of metabolites such as BCAAs (valine, leucine, and isoleucine) in the biofluids (urine and saliva) of subjects, before and after regular consumption of fruit kefir.

OTHER

Consumption of fruit kefir

Consumption of fruit kefir and measurement of the concentrations of metabolites such as BCAAs (valine, leucine, and isoleucine) in the biofluids (urine and saliva) of subjects, before and after regular consumption of fruit kefir.

OTHER

Consumption of micro-filtered fruit kefir

Consumption of micro-filtered fruit kefir and measurement of the concentrations of metabolites such as BCAAs (valine, leucine, and isoleucine) in the biofluids (urine and saliva) of subjects, before and after regular consumption of fruit kefir.

Sponsors & Collaborators

  • Centre National de la Recherche Scientifique, France

    collaborator OTHER

  • Sys2Diag

    lead OTHER_GOV

Principal Investigators

  • Laurence MOLINA, PhD · Sys2Diag

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-04
Primary Completion
2025-06-11
Completion
2027-06-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07522372 on ClinicalTrials.gov